- Home
- DMAC vs JOUT Comparison
DMAC vs JOUT Comparison
Compare DMAC & JOUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- JOUT
- Stock Information
- Founded
- DMAC 2000
- JOUT 1970
- Country
- DMAC United States
- JOUT United States
- Employees
- DMAC N/A
- JOUT N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- JOUT Recreational Games/Products/Toys
- Sector
- DMAC Health Care
- JOUT Consumer Discretionary
- Exchange
- DMAC Nasdaq
- JOUT Nasdaq
- Market Cap
- DMAC 260.0M
- JOUT 297.3M
- IPO Year
- DMAC N/A
- JOUT N/A
- Fundamental
- Price
- DMAC $4.76
- JOUT $33.32
- Analyst Decision
- DMAC Strong Buy
- JOUT
- Analyst Count
- DMAC 4
- JOUT 0
- Target Price
- DMAC $10.75
- JOUT N/A
- AVG Volume (30 Days)
- DMAC 353.4K
- JOUT 61.1K
- Earning Date
- DMAC 08-06-2025
- JOUT 08-01-2025
- Dividend Yield
- DMAC N/A
- JOUT 3.96%
- EPS Growth
- DMAC N/A
- JOUT N/A
- EPS
- DMAC N/A
- JOUT N/A
- Revenue
- DMAC N/A
- JOUT $554,344,000.00
- Revenue This Year
- DMAC N/A
- JOUT N/A
- Revenue Next Year
- DMAC N/A
- JOUT $12.02
- P/E Ratio
- DMAC N/A
- JOUT N/A
- Revenue Growth
- DMAC N/A
- JOUT N/A
- 52 Week Low
- DMAC $3.19
- JOUT $21.33
- 52 Week High
- DMAC $6.82
- JOUT $43.13
- Technical
- Relative Strength Index (RSI)
- DMAC 64.04
- JOUT 64.64
- Support Level
- DMAC $4.81
- JOUT $32.62
- Resistance Level
- DMAC $5.60
- JOUT $34.01
- Average True Range (ATR)
- DMAC 0.45
- JOUT 1.12
- MACD
- DMAC 0.11
- JOUT 0.09
- Stochastic Oscillator
- DMAC 67.90
- JOUT 86.34
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About JOUT Johnson Outdoors Inc.
Johnson Outdoors Inc is a manufacturer and marketer of branded seasonal, outdoor recreation products used for fishing from a boat, diving, paddling, hiking and camping. The company has four operating segment: Fishing, Camping, Watercraft Recreation, and Diving. It generates maximum revenue from the Fishing segment which produces and markets products under different brands such as Minn Kota electric motors for quiet trolling or primary propulsion, marine battery chargers and shallow water anchors; Humminbird sonar and GPS equipment for fish finding, navigation and marine cartography; and Cannon downriggers for controlled-depth fishing. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, Canada, and other regions.